Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D ...

Premium Quality Power IPO Day 2 Highlights: The subscription period for the Quality Power IPO is scheduled from Friday, February 14, to Tuesday, February 18. Quality Power IPO Day 2 Highlights ...

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

A man has been arrested on suspicion of attempted murder after a van struck two people in Poulton Le-Fylde just after midnight. Police received a report at 12.50am today, Sunday, that a Ford ...

The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...

It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth. Click here to read why ALNY is a Buy.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and ...

Alnylam's lead candidate for ATTR-CM, Amvuttra (vutrisiran), has shown promising results in the HELIOS-B clinical trial. The top-line data demonstrated a significant reduction in mortality ...

Management has forecast top sales of $5 billion for brensocatib in NCFB alone. 4. Alnylam’s Amvuttra/vutrisiran (ATTR-CM) Alnylam’s key pipeline drug, Amvuttra (vutrisiran) has an FDA decision date of ...